Compare · HCXY vs PBIO
HCXY vs PBIO
Side-by-side comparison of Hercules Capital, Inc. (HCXY) and Pressure BioSciences, Inc. (PBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HCXY and PBIO operate in n/a (n/a), so they compete in similar markets.
- HCXY carries a market cap of $4.52B.
Pressure BioSciences, Inc.
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the Americas, Europe, Asia, Africa, and Australia. Its pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. It serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. Pressure BioSciences, Inc. has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts.
Latest HCXY
- Hercules Capital Announces Date of 2026 Annual Meeting of Stockholders
- Hercules Capital Reports First Quarter 2026 Financial Results
- Hercules Capital Enters Next Phase of Growth with Expanded Leadership Team
- Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the First Quarter 2026
- Hercules Capital Announces Date for Release of First Quarter 2026 Financial Results and Conference Call
- Hercules Capital Sets New Record with All-Time High New Debt and Equity Commitments
- Hercules Capital Receives a BBB (high) Affirmed Investment Grade Corporate and Credit Rating from Morningstar DBRS
- Hercules Capital Named 2025 Americas BDC Manager of the Year by Private Debt Investor
- Hercules Capital Reports Fourth Quarter and Full-Year 2025 Financial Results
- Hercules Capital Closes Institutional Notes Offering of $300.0 Million 5.350% Unsecured Notes due 2029
Latest PBIO
- SEC Form 10-Q filed by Pressure BioSciences, Inc.
- Director Peterson Jeffrey N acquired $1,670 worth of shares (59,652 units at $0.03), increasing direct ownership by 72% to 142,084 units (SEC Form 4)
- Director Urdea Michael S acquired $404 worth of shares (14,429 units at $0.03), increasing direct ownership by 44% to 47,588 units (SEC Form 4)
- President, CEO Schumacher Richard T acquired $641 worth of shares (22,878 units at $0.03), increasing direct ownership by 38% to 82,967 units (SEC Form 4)
- Director Lazarev Alexander V acquired $528 worth of shares (18,863 units at $0.03), increasing direct ownership by 102% to 37,400 units (SEC Form 4)
- SEC Form 10-Q filed by Pressure BioSciences, Inc.
- SEC Form NT 10-Q filed by Pressure BioSciences, Inc.
- Pressure BioSciences, Inc. filed SEC Form 8-K: Other Events
- Pressure BioSciences, Inc. filed SEC Form 8-K: Leadership Update
- Pressure BioSciences, Inc. to Host Business and Financial Update on Thursday, June 20th at 4:30pm ET